(CercleFinance.com) – Alcon advances by more than 1% in Zurich, the day after the publication by the ophthalmology laboratory of an adjusted EPS of 2.24 dollars, up 4% in published data and 23% at constant exchange rates, for the year 2022.
At 8.65 billion dollars, its turnover increased by 5% (+11% at constant exchange rates), growth driven above all by the surgical division, while its adjusted operating margin improved by 0, 6 points at 18.2%.
“Alcon had a solid year despite a still challenging macroeconomic environment, including inflationary pressures, supply chain headwinds and a strong dollar,” said CEO David Endicott.
For 2023, management anticipates ‘mid to high single digit’ sales growth, continued margin expansion and earnings growth in the high 10-20% range.
Copyright (c) 2023 CercleFinance.com. All rights reserved.